Notable

Notable, founded in 2014, is a transformative presence in the Biotechnology and Health Care industries. Headquartered in the United States, the company is committed to revolutionizing cancer treatment, as encapsulated in its slogan: "Notable is a mission-driven company transforming the way cancer is treated."

As a clinical-stage platform therapeutic company, Notable develops a novel class of medicines termed predictive precision medicines. Their proprietary Predictive Precision Medicines Platform can replicate ex vivo clinical responses to cancer treatments, integrating biological assay conditions, dynamic signal analysis, and AI-driven predictive algorithms. This allows for the early identification of clinically responsive patients, potentially accelerating both development timelines and market entry.

The company's strategy, underscored by a targeted in-licensing model, aims at delivering enhanced medical impact and commercial viability. Notable received a Series B investment on 01 July 2022 from investors including Duro Ventures, Bioverge Ventures, and Milad Alucozai, positioning itself strongly for future growth within its sector.